Provided by Tiger Fintech (Singapore) Pte. Ltd.

AstraZeneca PLC

75.96
-1.5400-1.99%
Volume:4.88M
Turnover:372.73M
Market Cap:235.57B
PE:33.76
High:76.97
Open:76.11
Low:75.48
Close:77.50
Loading ...

Camizestrant demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival in 1st-line advanced HR-positive breast cancer with an emergent ESR1 tumor mutation in SERENA-6 Phase III trial

Business Wire
·
26 Feb

AstraZeneca (AZN) Gets a Buy from Bernstein

TIPRANKS
·
26 Feb

AstraZeneca's Cancer Drug Pipeline Could Fuel $80 Billion Sales Target -- Market Talk

Dow Jones
·
26 Feb

Berenberg Bank Sticks to Its Buy Rating for AstraZeneca (AZN)

TIPRANKS
·
26 Feb

AIM ImmunoTech Doses First Subject in Phase 2 of Late-Stage Pancreatic Cancer Study

MT Newswires Live
·
26 Feb

AstraZeneca PLC (AZN): A High Growth Mega Cap Stock You Can Buy and Hold for the Next 5 Years

Insider Monkey
·
25 Feb

AstraZeneca PLC Stock Rises Monday, Outperforms Market

Dow Jones
·
25 Feb

AstraZeneca PLC (AZN): Among the Cheap Pharmaceutical Stocks to Buy According to Analysts

Insider Monkey
·
23 Feb

Q4 2024 Ionis Pharmaceuticals Inc Earnings Call

Thomson Reuters StreetEvents
·
20 Feb

AstraZeneca Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.
·
20 Feb

AstraZeneca (AZN) Gets a Buy from J.P. Morgan

TIPRANKS
·
19 Feb

AstraZeneca PLC ADR Outperforms Competitors On Strong Trading Day

Dow Jones
·
19 Feb

AstraZeneca PLC Stock Rises Tuesday, Underperforms Market

Dow Jones
·
19 Feb

AstraZeneca (LON:AZN) Is Posting Promising Earnings But The Good News Doesn’t Stop There

Simply Wall St.
·
18 Feb

AstraZeneca's Bladder Cancer Treatment Improves Survival in Phase 3 Trial

MT Newswires Live
·
15 Feb

AstraZeneca: IMFINZI improved event-free survival, OS across MIBC

TIPRANKS
·
15 Feb